Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Retraction Note

Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor

Authors: Xiaoling Du, Jilong Yang, Antti Ylipää, Ze Zhu

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Excerpt

The Editor-in-Chief has retracted this article because of substantial text overlap with a previously published article by some of the same authors (1) and apparent re-use of some of the data shown in the figures with different labelling. Specifically:
  • In Fig. 4a some Western blots appear to be very similar or to overlap with those presented in Fig. 3A in (1).
  • Figure 4c appears to contain an image that overlaps with Fig. 3B in (1). Both images are described as “ST88-14 cell line, control siRNA”; however, the two figures purport to describe separate and different experiments.
Corresponding author Yang has confirmed that both articles are based on the same patient population and sample collection. Although the earlier study [1] is cited in the 2013 article, it was not made clear that this was a continuation of the same work by a subset of authors. Corresponding author Yang has stated that the original data are not available. …
Metadata
Title
Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor
Authors
Xiaoling Du
Jilong Yang
Antti Ylipää
Ze Zhu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01380-7

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine